CN114409654A - Intermediate synthesis method of BTK inhibitor - Google Patents
Intermediate synthesis method of BTK inhibitor Download PDFInfo
- Publication number
- CN114409654A CN114409654A CN202111659739.XA CN202111659739A CN114409654A CN 114409654 A CN114409654 A CN 114409654A CN 202111659739 A CN202111659739 A CN 202111659739A CN 114409654 A CN114409654 A CN 114409654A
- Authority
- CN
- China
- Prior art keywords
- btk inhibitor
- reaction
- solution
- compound
- synthesizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides a synthesis method of an intermediate of a BTK inhibitor, which comprises the following steps: will contain a compoundThe organic solution reacts with an organic solution of a format reagent isopropyl magnesium chloride lithium chloride to obtain a reaction solution A; reacting the reaction solution A with a compoundAfter the reaction, the organic solution is added into an ammonium chloride solution for quenching, then extraction and layering are carried out, and the organic layer is decompressed and concentrated to obtain an intermediate of the target compound BTK inhibitor. The synthesis method provided by the invention has the advantages of mild reaction conditions, sufficient raw material conversion, high yield of the obtained compound and less impurities.
Description
Technical Field
The invention relates to the technical field of organic synthesis, in particular to a method for synthesizing an intermediate of a BTK inhibitor.
Background
As the process advances, the intermediate requirements for BTK inhibitors increase, and the preformulations do not match: under the existing synthesis method for producing the intermediate of the BTK inhibitor, the dangerous material butyl lithium is mainly used as a raw material and needs to be carried out under severe reaction conditions such as ultralow temperature and the like, so that the preparation of the intermediate of the BTK inhibitor is limited.
Because the intermediate compound of the BTK inhibitor in the prior art has poor safety, harsh reaction conditions, low production efficiency and many defects, a compound preparation method which has good safety, mild reaction conditions, high production efficiency and easy operation is needed on the basis. In view of the above, the present application proposes a method for synthesizing an intermediate of a BTK inhibitor.
Disclosure of Invention
The invention aims to provide a method for synthesizing an intermediate of a BTK inhibitor, which has the advantages of good safety, mild reaction conditions, high production efficiency and easiness in operation.
The invention adopts the following technical scheme to solve the technical problems:
a method for synthesizing an intermediate of a BTK inhibitor, comprising the steps of:
(1) will contain a compoundThe organic solution reacts with an organic solution of a format reagent isopropyl magnesium chloride lithium chloride to obtain a reaction solution A;
(2) reacting the reaction solution A with a compoundAfter the reaction, the organic solution is added into an ammonium chloride solution for quenching, then extraction and layering are carried out, and the organic layer is decompressed and concentrated to obtain an intermediate of the target compound BTK inhibitor.
The specific reaction equation is as follows:
further, the solvent used in the organic solution includes tetrahydrofuran.
Further, the reaction temperature in the step (1) is-10-5 ℃, and the reaction time is 1-4 hours.
Further, the reaction temperature in the step (2) is-10-5 ℃, and the reaction time is 2-6 h.
Further, the concentration of the ammonium chloride is 10-30%.
Further, the extract was ethyl acetate.
Furthermore, the internal temperature in the decompression concentration process is less than or equal to 45 ℃, and the vacuum degree is less than or equal to 0.08 Mpa.
The invention has the advantages that:
the invention aims to overcome the defects of poor safety, harsh reaction conditions, low production efficiency and the like in the compound preparation process in the prior art, and provides a compound preparation method which has the advantages of good safety, mild reaction conditions, high production efficiency and easiness in operation. The method avoids using dangerous material butyl lithium, and can obtain yield higher than the original reaction condition without reacting under ultralow temperature. The process has the advantages of mild reaction conditions, full conversion of raw materials, high yield of the obtained compound and less impurities.
Drawings
FIG. 1 is a liquid chromatogram of an intermediate prepared to yield a BTK inhibitor using a prior art synthetic route;
FIG. 2 is a liquid chromatogram of an intermediate of a BTK inhibitor in example 1 of the present invention.
Detailed Description
The invention is further illustrated by the following examples, which are intended to illustrate, but not to limit the invention further.
In the prior art, an organic solution containing a compound I and an organic solution containing butyl lithium react at a temperature of-65 to-80 ℃ to obtain a reaction solution, then the reaction solution reacts with an organic solution containing a compound II at a temperature of-65 to-80 ℃, the reaction solution is added into an ammonium chloride solution for quenching, then a solvent ethyl acetate is used for extraction and delamination, an organic layer is concentrated, and the ethyl acetate is used for pulping and filtering to obtain an intermediate of a target compound BTK inhibitor; the specific reaction equation is as follows:
the invention provides another intermediate synthesis method of the BTK inhibitor, which avoids using dangerous material butyl lithium and can obtain yield higher than the original reaction condition without reacting under ultralow temperature.
In the invention, the prior art is improved, and a method for synthesizing an intermediate of a BTK inhibitor is provided, which comprises the following steps:
(1) will contain a compoundThe organic solution reacts with an organic solution of a format reagent isopropyl magnesium chloride lithium chloride to obtain a reaction solution A;
(2) reacting the reaction solution A with a compoundAfter the reaction, the organic solution is added into an ammonium chloride solution for quenching, then extraction and layering are carried out, and the organic layer is decompressed and concentrated to obtain an intermediate of the target compound BTK inhibitor.
Wherein the solvent used in the organic solution comprises tetrahydrofuran; the reaction temperature in the step (1) is-10-5 ℃, and the reaction time is 1-4 h; the reaction temperature in the step (2) is-10-5 ℃, and the reaction time is 2-6 h; the concentration of the ammonium chloride is 10-30%; the extract liquor is ethyl acetate; the internal temperature in the decompression concentration process is less than or equal to 45 ℃, and the vacuum degree is less than or equal to 0.08 Mpa.
The following specific examples are provided to further illustrate the present invention by way of preferred examples only and are not intended to represent limiting reaction conditions for the synthesis provided by the present invention:
example 1
Example 1 providesA method for synthesizing an intermediate of a BTK inhibitor, comprising the steps of: containing compounds IReacting the tetrahydrofuran organic solution with a tetrahydrofuran organic solution of a format reagent isopropyl magnesium chloride lithium chloride at 0 ℃ for 1 hour to obtain a reaction solution, and then reacting the reaction solution with a compound IIReacting the tetrahydrofuran organic solution for 2 hours at 0 ℃, adding the tetrahydrofuran organic solution into an ammonium chloride solution with the concentration of 20 percent for quenching, extracting by using a solvent of ethyl acetate, layering, concentrating the organic layer under reduced pressure at the internal temperature of 45 ℃ and the vacuum degree of 0.08Mpa, pulping by using ethyl acetate, and filtering to obtain an intermediate of the target compound BTK inhibitor.
The specific reaction equation is as follows:
the product prepared in the prior art was subjected to liquid chromatography analysis tests under the following conditions in table 1:
table 1: purity chromatography method-liquid phase
The liquid chromatogram obtained according to the above test conditions is shown in fig. 1 and 2, the data of the liquid chromatogram in fig. 1 corresponds to table 2 below, and the data of the liquid chromatogram in fig. 2 corresponds to table 3 below.
Table 2:
as can be seen from fig. 1 and table 2: the product peaks at 21.6min, the liquid phase purity is 96.39%, the impurity content is more, and the impurity content exceeds 0.5% in 21.8min and 25.8 min; the quality of the product is poor.
Table 3:
time of liquid phase peak | Peak area | Peak area ratio | Peak height | |
1 | 9.729 | 9237 | 0.073 | 693 |
2 | 17.626 | 6005 | 0.047 | 1740 |
3 | 18.680 | 1121 | 0.009 | 166 |
4 | 19.383 | 2141 | 0.017 | 658 |
5 | 19.569 | 1123 | 0.009 | 417 |
6 | 20.339 | 1771 | 0.014 | 629 |
7 | 20.705 | 4334 | 0.034 | 1512 |
8 | 21.529 | 12380697 | 97.675 | 3584282 |
9 | 21.695 | 47110 | 0.372 | 12588 |
10 | 21.794 | 52927 | 0.418 | 16047 |
11 | 22.498 | 4788 | 0.038 | 1644 |
12 | 22.921 | 2419 | 0.019 | 872 |
13 | 22.988 | 1994 | 0.009 | 393 |
As can be seen from fig. 2 and table 3: the product peaks at 21.6min, the liquid phase purity is 97.67%, and all other impurities are less than 0.5%; meets the quality standard of the product.
Finally, it should be noted that: the above embodiments are only used to illustrate the present invention and do not limit the technical solutions described in the present invention; it will be understood by those skilled in the art that the present invention may be modified and equivalents may be substituted; all such modifications and variations are intended to be included herein within the scope of this disclosure and the present invention and protected by the following claims.
Claims (7)
1. A method for synthesizing an intermediate of a BTK inhibitor is characterized by comprising the following steps:
(1) will contain a compoundThe organic solution reacts with an organic solution of a format reagent isopropyl magnesium chloride lithium chloride to obtain a reaction solution A;
(2) reacting the reaction solution A with a compoundAfter the reaction, the organic solution is added into an ammonium chloride solution for quenching, then extraction and layering are carried out, and the organic layer is decompressed and concentrated to obtain an intermediate of the target compound BTK inhibitor.
2. A process of synthesizing an intermediate of a BTK inhibitor according to claim 1, wherein the solvent used in the organic solution comprises tetrahydrofuran.
3. The method for synthesizing the intermediate of a BTK inhibitor according to claim 2, wherein the reaction temperature in the step (1) is-10 to 5 ℃ and the reaction time is 1 to 4 hours.
4. The method for synthesizing the intermediate of a BTK inhibitor according to claim 1, wherein the reaction temperature in the step (2) is-10 to 5 ℃ and the reaction time is 2 to 6 hours.
5. A process according to claim 1, wherein the concentration of ammonium chloride is 10-30%.
6. A process of synthesizing an intermediate of a BTK inhibitor according to claim 1, wherein said extract is ethyl acetate.
7. The method for synthesizing the intermediate of a BTK inhibitor according to claim 1, wherein the internal temperature during the vacuum concentration is not more than 45 ℃ and the vacuum degree is not more than 0.08 MPa.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111659739.XA CN114409654A (en) | 2021-12-30 | 2021-12-30 | Intermediate synthesis method of BTK inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111659739.XA CN114409654A (en) | 2021-12-30 | 2021-12-30 | Intermediate synthesis method of BTK inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114409654A true CN114409654A (en) | 2022-04-29 |
Family
ID=81270517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111659739.XA Pending CN114409654A (en) | 2021-12-30 | 2021-12-30 | Intermediate synthesis method of BTK inhibitor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114409654A (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0578362A (en) * | 1990-01-16 | 1993-03-30 | Takeda Chem Ind Ltd | Condensed heterocyclic compound, its production and use, and intermediate therefor |
WO2006090261A1 (en) * | 2005-02-24 | 2006-08-31 | Pfizer Products Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
US20090286783A1 (en) * | 2008-05-19 | 2009-11-19 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20160257689A1 (en) * | 2015-02-27 | 2016-09-08 | Incyte Corporation | Salts and processes of preparing a pi3k inhibitor |
WO2017111787A1 (en) * | 2015-12-23 | 2017-06-29 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
CN109890821A (en) * | 2016-08-24 | 2019-06-14 | 艾科尔公司 | Amino-pyrrolopyrimidine ketone compound and its application method |
CN110759916A (en) * | 2014-08-15 | 2020-02-07 | 正大天晴药业集团股份有限公司 | Pyrrolopyrimidines as TLR7 agonists |
WO2020239124A1 (en) * | 2019-05-31 | 2020-12-03 | Fochon Pharmaceuticals, Ltd. | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS |
WO2021202688A1 (en) * | 2020-04-02 | 2021-10-07 | Gilead Sciences, Inc. | Process for preparing a cot inhibitor compound |
-
2021
- 2021-12-30 CN CN202111659739.XA patent/CN114409654A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0578362A (en) * | 1990-01-16 | 1993-03-30 | Takeda Chem Ind Ltd | Condensed heterocyclic compound, its production and use, and intermediate therefor |
WO2006090261A1 (en) * | 2005-02-24 | 2006-08-31 | Pfizer Products Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
US20090111805A1 (en) * | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
US20090286783A1 (en) * | 2008-05-19 | 2009-11-19 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN110759916A (en) * | 2014-08-15 | 2020-02-07 | 正大天晴药业集团股份有限公司 | Pyrrolopyrimidines as TLR7 agonists |
US20160257689A1 (en) * | 2015-02-27 | 2016-09-08 | Incyte Corporation | Salts and processes of preparing a pi3k inhibitor |
WO2017111787A1 (en) * | 2015-12-23 | 2017-06-29 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
CN109890821A (en) * | 2016-08-24 | 2019-06-14 | 艾科尔公司 | Amino-pyrrolopyrimidine ketone compound and its application method |
WO2020239124A1 (en) * | 2019-05-31 | 2020-12-03 | Fochon Pharmaceuticals, Ltd. | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS |
WO2021202688A1 (en) * | 2020-04-02 | 2021-10-07 | Gilead Sciences, Inc. | Process for preparing a cot inhibitor compound |
Non-Patent Citations (2)
Title |
---|
刘雨燕 等: "LiCl 促进的多官能团格氏试剂的制备及应用研究进展", 《有机化学》 * |
黄淑娟: "新型BTK抑制剂Abivertinib在急性髓细胞白血病中的应用及其作用机制研究", 《中国博士学位论文全文数据库医药卫生科技辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109336831B (en) | Method for recovering triazine ring from triazine ring wastewater | |
US20150094498A1 (en) | Processes and systems for the production of propylene glycol from glycerol | |
CN113429275B (en) | Method for reducing production cost of pseudo ionone | |
CN107935970B (en) | Preparation method of high-purity low-water-content 3-methylamine tetrahydrofuran | |
CN114409654A (en) | Intermediate synthesis method of BTK inhibitor | |
CN111039801A (en) | Utilization method of cyclohexane oxidation by-product light oil | |
CN114835661A (en) | Industrial preparation method of a-acetyl-r-butyrolactone | |
CN107778141B (en) | Purification method of 1, 4-butanediol | |
CN110577491B (en) | Method for preparing 2-chloro-5-chloromethyl pyridine | |
CN110835296B (en) | Preparation process of 2,2, 4-trimethyl-3-hydroxypentanoic acid | |
CN110105341B (en) | Recycling process of excessive triazole potassium in propiconazole synthesis | |
CN114105802A (en) | Method for controlling metal ions and chromaticity in preparation process of N-ethylformamide | |
CN113548952A (en) | Preparation method of high-quality pseudo ionone | |
CN112479938A (en) | Preparation method of N-cyclohexyl-2-aminoethanesulfonic acid | |
CN108147988B (en) | Preparation method of lactam compound with high chiral purity | |
CN112679512A (en) | Tributine intermediate and preparation method thereof | |
CN114213266B (en) | Synthesis process of high-purity D-N- (2, 6-xylyl) alanine methyl ester | |
CN111057017B (en) | Method for recovering 3-mercapto-5-methyl-1, 2, 4-triazole from triazine ring cyclization mother liquor | |
CN114736103B (en) | Method for separating propyl guaiacol and propyl syringol from lignin oil | |
CN115636742B (en) | Recrystallization method | |
CN113387981B (en) | Synthesis method of diethyl phosphite | |
CN112876438B (en) | Separation and purification method of high-purity 3-acetamido-5-acetylfuran | |
CN106947791B (en) | Method for synthesizing atazanavir intermediate chlorohydrin by using biological enzyme catalysis | |
CN117402071A (en) | Post-treatment method of aniline-nitrobenzene condensation reducing solution | |
CN203333539U (en) | Separation and recovery device of alcoholysis liquid waste in polyvinyl alcohol production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |